Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship of Riboflavin and Niacin with Cardiovascular Disease

심혈관 질환과 리보플라빈 및 나이아신과의 상관성 연구

  • Ahn, Ji Yeong (Department of Biomedical Laboratory Science, School of Medicine, Eulji University) ;
  • Kim, In Sik (Department of Biomedical Laboratory Science, School of Medicine, Eulji University) ;
  • Lee, Ji-Sook (Department of Clinical Laboratory Science, Wonkwang Health Science University)
  • 안지영 (을지대학교 대전캠퍼스 임상병리학과) ;
  • 김인식 (을지대학교 대전캠퍼스 임상병리학과) ;
  • 이지숙 (원광보건대학교 임상병리과)
  • Received : 2019.09.24
  • Accepted : 2019.11.03
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cardiovascular disease is caused by different factors. These factors include innateness factors such as aging, biological factors such as high blood pressure, and environmental factors such as stress. This study examined the factors associated with cardiovascular disease and the ways to reduce its prevalence by analyzing the data within the Korean National Health and Nutrition Examination Reports from 2013 to 2017, and particularly the survey and examination data for people over 50 years old. The study population was divided into two groups: members of the first group consumed riboflavin and niacin at the recommended rate while those in the second group did not. Riboflavin intake was correlated with hypertension, hyperglycemia, and a low HDL-cholesterol level, whereas niacin intake was correlated with hypertension, hyperglycemia, waist size, and a low HDL-cholesterol level. The combination of niacin and riboflavin intakes was correlated with hypertension, hyperglycemia, waist size, and a low HDL-cholesterol level (P<0.05). The combined intake of the recommended levels of riboflavin and niacin reduced the average physiological factor abnormality rate to 80%. Taken together, the beneficial effects of riboflavin and niacin can reduce the prevalence of cardiovascular disease.

심혈관 질환의 위험 요인은 선천적으로 노화, 당 대사의 문제, 가족력과 성별이 있으며 생리학적 요인으로 고혈압, 혈청 콜레스테롤이 있다. 그 외 환경적 요인으로 흡연, 섭식, 스트레스 등이 있다. 본 연구는 최근 2013~2017년 국민건강영양조사 내용을 바탕으로 50세이상 남녀를 대상으로 한 건강설문조사와 검진조사를 이용하여 심혈관 질환의 위험 요인 및 유병률을 낮출 수 있는 방법을 연구하고자 하였다. 생리학적 요소와 영양성분 권장섭취 여부와의 상관성을 보기 위해 리보플라빈과 나이아신의 권장량을 확인하여 권장섭취군과 비권장섭취군으로 나눈 후 생리학적 요소변수와 분석하였다. 리보플라빈은 고혈압, 고혈당, 낮은 HDL-콜레스테롤에서, 나이아신은 고혈압, 고혈당, 허리둘레, 낮은 HDL-콜레스테롤에서, 둘을 복합적으로 보았을 때는 고혈압, 고혈당, 허리 둘레, 낮은 HDL-콜레스테롤에서 상관성이 있는 것으로 나타났다 (P<0.05). 결론적으로 리보플라빈, 나이아신의 권장섭취는 고혈당, 허리 둘레, HDL-콜레스테롤 등의 생리학적 요소에 영향을 줄 수 있으며, 이를 통해 심혈관 질환의 유병률을 낮출 수 있다. 이는 심혈관 질환의 위험율을 낮출 수 있는 가치 있는 연구로서 의의가 있다고 사료된다.

Keywords

References

  1. Ko HJ, Youn CH. The association between serum gamma-glutamyl transferase within normal range and risk factors of cardiovascular diseases: Based on the framingham risk score. Korean J Obes. 2013;22:261-263. https://doi.org/10.7570/kjo.2013.22.4.261
  2. Youn SI, Moun JS, Sin C, Park HY, Lee JB, Jo IH. SNP study of the endothelial NO Synthase as risk factor for cardiovascular diseases in Koreans. Report of National Institute of Health. 2000;37:400-404.
  3. Lee SW, Kim HC, Suh HS, Suh I. Thirty-year trends in mortality from cardiovascular diseases in Korea. Korean Circ J. 2015;45:202-209. https://doi.org/10.4070/kcj.2015.45.3.202
  4. Xu L, Ryu S, Goong H. Gender differences in predictors of health behaviors modification among patients with cardiovascular disease. JKCA. 2015;15:280-289.
  5. Cho JJ, Kim JY, Byun JS. Occupational stress on risk factors for cardiovascular diseases and metabolic syndrome. Ann Occup Environ Med. 2006;18:209-220.
  6. Jee SH, Song JW, Cho HK, Kim S, Jang YS, Kim JH. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea. J Lipid Atheroscler. 2004;14:153-168.
  7. Hoppel C, Dimarco JP, Tandler B. Riboflavin and rat hepatic cell structure and function, mitochondrial oxidative metabolism in deficiency states. J Biol chem. 1979;254:4164-4170. https://doi.org/10.1016/S0021-9258(18)50710-9
  8. Sugioka G, Porta EA, Corey PN, Hartoft WS. The liver of rats fed riboflav in-deficient diet at two levels of protein. Am J Pathol. 1969;54:1-19.
  9. Mielgo-Ayuso J, Aparicio-Ugarriza R, Otza J, Aranceta-Bartrina J, Gil A,Ortega RM. et al. Dietary intake and food sources of niacin, riboflavin, thiamin and vitamin B6 in a representative sample of the Spanish population. The ANIBES Study. Nutrients. 2018;10:846. https://doi.org/10.3390/nu10070846
  10. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase ${\beta}$ chain in HepG2 cells: implications for raising HDL. J Lipid Res. 2008;49:1195-1201. https://doi.org/10.1194/jlr.M700426-JLR200
  11. Braun MM, Stevens WA, Barstow CH. Stable coronary artery disease: treatment. Am Fam Physician. 2018;97:376-384.
  12. Pisarik P. Evidence supporting niacin therapy is more nuanced than article states. Am Fam Physician. 2018;98:630-631.
  13. Choi JY, Kim YN, Cho YO. Evaluation of riboflavin intakes and status of 20-64-year-old adults in South Korea. Nutrients. 2015;7:253-264. https://doi.org/10.3390/nu7010253
  14. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014;43:69-77. https://doi.org/10.1093/ije/dyt228
  15. Korea Centers for Disease Control and Prevention. Metabolic syndrome [Internet] Cheongju: Korea Centers for Disease Control and Prevention; 2016 [cited by 2019 Oct 10]. Available from: http://health.cdc.go.kr/health/HealthInfoArea/HealthInfo/View.do?idx=490&page=1&sortType=date&dept=&category_code=&category=1&searchField=titleAndSummary&searchWord=&dateSelect=1&fromDate=&toDate=.
  16. Ministry of Health. Dietary reference intakes for Koreans [Internet] Sejong: Ministry of Health; 2019 [cited by 2019 Ocyt 10]. Available from: http://www.mohw.go.kr/react/jb/sjb030301vw.jsp? PAR_MENU_ID=03&MENU_ID=032901&CONT_SEQ=337356.
  17. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease. Prevention and control. The World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. Geneva, Switzerland. 2011;1:1-153.
  18. Kim JS, Kim SS, Jung JK, Kim YD, Youn SJ, Kim JY, et al. Association of abdominal aortic calcification with lifestyle and risk factors of cardiovascular disease. Korean J Fam Med. 2013;34:213-220. https://doi.org/10.4082/kjfm.2013.34.3.213
  19. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update a report from the American heart association. Circulation. 2015;131:E29-322.
  20. Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Can J Cardiol. 2014;30:553-559. https://doi.org/10.1016/j.cjca.2014.02.014
  21. Peter SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383:1973-1980. https://doi.org/10.1016/S0140-6736(14)60040-4
  22. Bae YH, Lee KW. Risk factors for cardiovascular disease in adults aged 30 years and older. Journal of The Korean Society of Integrative Medicine. 2016;4:97-107. https://doi.org/10.15268/ksim.2016.4.2.097
  23. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, et al. High-density lipoproteins: A consensus statement from the national lipid association. J Clin Lipidol. 2013;7:484-525. https://doi.org/10.1016/j.jacl.2013.08.001
  24. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons SR, et al. 2013 ACC /AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;1:2935-2959.
  25. Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;16:607-617. https://doi.org/10.1016/S0140-6736(14)61009-6
  26. Huxley R, Lewington S, Clarke R. Cholesterol, coronary heart disease and stroke: a review of published evidence from observational studies and randomized controlled trials. Semin Vasc Med. 2002;2:315-323. https://doi.org/10.1055/s-2002-35402
  27. Ragland DR, Brand RJ. Coronary heart disease mortality in the western collaborative group study, follow-up experience of 22 years. Am J Epidemiol. 1988;127:462-475. https://doi.org/10.1093/oxfordjournals.aje.a114823
  28. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the copenhagen male study. Circulation. 1998;97:1029-1036. https://doi.org/10.1161/01.CIR.97.11.1029
  29. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2078-2086.
  30. Park JK, Kim HJ, Park KS, Lee SS, Chang SJ, Shin KC, et al. The case-control study on the risk factors of cerebrovascular diseases and coronary heart diseases. J Prev Med Public Health. 1996;29:639-655.
  31. Sin SH, Lee TY. Associations of serum lipid profiles with incidence of ischemic heart diseases in Korean adults: Retrospective Cohort Study. Journal of Korea Academia-Industrial cooperation Society. 2012;13:2219-2231. https://doi.org/10.5762/KAIS.2012.13.5.2219
  32. Jee SH, Song JW, Cho HK, Kim S, Jang YS, Kim JH. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea. J Lipid Atheroscler. 2004;14:153-168.
  33. National Heart, Lung, and Blood Institute (NHLBI). Epidemiology and prevention of cardiovascular disease. Bethesda. 1994.
  34. Choi MC, Song YH, Rhee SY, Woo JT. Frammingham risk scores by occupational group based on the 3rd Korean National Health and Nutrition Examination Survey. Ann Occup Environ Med. 2009;21:63-75.
  35. Cho EY, Bae SJ, Cho HK, Ko YG, Park HY, Lee JH, et al. Association of cholesteryl ester transfer protein gene polymorphism with serum lipid concentration and coronary artery disease in Korean men. Korean Circ J. 2004;34:565-573. https://doi.org/10.4070/kcj.2004.34.6.565
  36. D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:E192224. https://doi.org/10.1001/jamanetworkopen.2019.2224
  37. Carretero OA, Oparil S. Essential hypertension, part 1: definition and etiology. Circulation. 2000;101:329-335. https://doi.org/10.1161/01.CIR.101.3.329
  38. Cutler JA. High blood pressure and end-organ damage. J Hypertens Suppl. 1996;14:3-6.
  39. National Health Insurance Corporation. Payment data of health insurance Korea 2006-2011 [Internet]. Wonju: National Health Insurance Corporation; 2019 [cited 2019 Oct 10]. Available from: https://www.nhis.or.kr/retrieveHomeMain.xx.

Cited by

  1. 제2형 당뇨병 환자의 비타민 B 섭취와 임상지표의 상관관계에 대한 연구 vol.35, pp.5, 2019, https://doi.org/10.7318/kjfc/2020.35.5.493